$77.7 Million is the total value of Kinnevik AB (publ)'s 1 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
RXRX | Buy | Recursion Pharmaceuticals, Inc. | $77,730,340 | +52.3% | 10,405,668 | +36.0% | 100.00% | +46.0% |
Exit | Babylon Holdings Ltd | $0 | – | -4,617,340 | -100.0% | -31.53% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-07-25
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Babylon Holdings Ltd | 6 | Q1 2023 | 44.6% |
Teladoc Health, Inc. | 5 | Q4 2022 | 78.3% |
Recursion Pharmaceuticals, Inc. | 4 | Q3 2023 | 100.0% |
View Kinnevik AB (publ)'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
RECURSION PHARMACEUTICALS, INC. | May 22, 2023 | 10,405,668 | 5.6% |
Babylon Holdings Ltd | November 14, 2022 | 115,433,522 | 18.6% |
Teladoc Health, Inc. | April 15, 2021 | 7,491,124 | 4.9% |
Livongo Health, Inc.Sold out | November 03, 2020 | 0 | 0.0% |
MILLICOM INTERNATIONAL CELLULAR SASold out | January 21, 2020 | 0 | 0.0% |
View Kinnevik AB (publ)'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-15 |
13F-HR | 2024-02-02 |
13F-HR | 2023-10-06 |
13F-HR | 2023-07-25 |
SC 13G | 2023-05-22 |
13F-HR | 2023-04-14 |
13F-HR | 2023-02-01 |
3 | 2022-12-30 |
SC 13D | 2022-11-14 |
13F-HR | 2022-10-25 |
View Kinnevik AB (publ)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.